Updated efficacy and safety of lorlatinib in a phase 2 study in Chinese patients with previously treated advanced ALK-positive non-small cell lung cancer
Article in Clinical Lung Cancer (April 2024)
The most recent citing publications are shown below. View all 15 publications that cite this research output on Dimensions.
Article in Clinical Lung Cancer (April 2024)
Article in Frontiers in Pharmacology (November 2023)
Article in ESMO Open (November 2023)